July 16, 2014
A New Era in Hepatitis C Treatment
Until recently, treating hepatitis C (HCV) required 24 weeks or more of weekly injections with a regimen including peginterferon alfa. These drug combinations often failed to cure the HCV infection and came with many side effects.
However, it's been a breakthrough year for HCV treatment, with many new, more effective and safer options taking the spotlight. Spearheading the way has been sofosbuvir (Sovaldi), a nucleotide polymerase inhibitor that allows for oral dosing, interferon-free treatment for many and a shorter treatment course.
But the drug's introduction -- and its high baseline price tag -- has stirred considerable debate. Let's examine the brief history of sofosbuvir and how its controversial price could impact future health care costs.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
|Weekly PRO 140 Antibody Injections May Work as HIV Maintenance Therapy|
|Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds|
|Fast Rebound After Treatment Interruption in 9 of 10 With Low HIV DNA Reservoir|
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|
|Which HIV Treatment Regimens Are Recommended for Newly Diagnosed Patients?|